neuroendocrine tumors/переутомление

Ссылка сохраняется в буфер обмена

Выберите тип сортировки

Страница 1 от 93 полученные результаты

Calcitonin-secreting pancreatic neuroendocrine tumors: a case report and review of the literature.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

OBJECTIVE We report the presentation and novel therapy of a calcitonin-secreting pancreatic neuroendocrine tumor (PNET) and review the literature on this unusual neoplasm. METHODS We cite the history of a 38-year-old male who presented with fatigue, weight loss, and diarrhea and was found to have a

Metastatic small bowel neuroendocrine tumour with bilateral carcinoid heart disease.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

A 63-year-old woman was admitted with a year's history of exertional breathlessness, anxiety attacks, syncopal episodes, diarrhoea, fatigue, reduced appetite, 2 stones weight loss, and flushing affecting her face and trunk. Investigations revealed raised urine 5-hydroxy indole acetic acid (5-HIAA)

Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Streptozocin (STZ) administration with or without other cytotoxic drugs remains a crucial chemotherapy for patients with advanced pancreatic neuroendocrine neoplasms (Pan-NENs). However, the therapeutic effects of combination treatment with weekly STZ and oral S-1 therapy (STS1) remain

Non-islet cell tumour hypoglycaemia in a patient with a well-differentiated gastric neuroendocrine tumour.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

A 61-year-old man, without noteworthy medical history, presented with complaints of progressive fatigue and flushes. Diagnostic imaging revealed a large tumour in the stomach with liver metastases, and histopathological examination showed a well-differentiated gastric neuroendocrine tumour (NET).

Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

BACKGROUND Neuroendocrine tumours (NETs) are rare, and when metastatic NETs are incurable, the tumours are frequently slowly growing. Patients may be confronted with disease-specific problems and distinct issues when accessing health-care. We aimed to assess perceptions of care coordination,

Practical guide to supportive care of patients with functional neuroendocrine tumors.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Supportive care of patients with functional neuroendocrine tumors (NETs) has evolved to include the use of multiple targeted agents to control paraneoplastic states and newer surgical and interventional radiologic techniques to reduce tumor bulk. Challenges encountered by the clinician are the

Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

BACKGROUND The objective of this paper was to assess the safety and efficacy of sunitinib malate in patients with well-differentiated metastatic pancreatic neuroendocrine neoplasms (PNENs) who relapsed on standard therapy. METHODS Overall, eight patients with well-differentiated pancreatic

Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

BACKGROUND Patients with advanced well-differentiated neuroendocrine tumours (Wd-NETs) are commonly treated with somatostatin analogues (SSAs). Some patients may develop SSA-related side effects such as pancreatic exocrine insufficiency (PEI). METHODS In this prospective, observational study, the

Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Objective: To examine patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who receive sequential treatment with somatostatin analogs. Materials and Methods: This retrospective chart review examined lanreotide depot/autogel tolerability and efficacy among

Carboplatin-related acute interstitial nephritis in a patient with pancreatic neuroendocrine tumor.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Carboplatin is characterized by low nephrotoxicity, including acute tubular necrosis (ATN), compared to a conventional platinum complex due to its low accumulative property in the renal tubules. Therefore, there are extremely few reports of carboplatin-induced kidney injury and only one case has

E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

CONCLUSIONS Rate of progression-free survival at a particular point in time, i.e., a landmark analysis, is a difficult endpoint for a heterogenous malignancy such as neuroendocrine cancer.Landmark analyses can also be complicated by evolution in the standard of care during the conduct of a clinical

Long-term survival of a patient with an inoperable thymic neuroendocrine tumor stage IIIa under sole treatment with Viscum album extract: A CARE compliant clinical case report.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Thymic neuroendocrine tumor (TNET) is very rare and characterized by a tendency to invade adjacent structures, frequent metastasis, resistance to therapy, and a poor prognosis. Viscum album extracts (VAE) have shown immunological, apoptogenic, and cytotoxic

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

BACKGROUND This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs). METHODS Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week

Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Neuroendocrine tumors (NETs) are understudied and have limited systemic treatment options. Prior studies for patients with advanced NETs have demonstrated promising results when antimetabolite agents, including fluoropyrimidines, were combined with temozolomide TMZ. TAS-102 (trifluridine/tipiracil)

FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

On May 20, 2011, the U.S. Food and Drug Administration (FDA) approved sunitinib malate capsules (Sutent®; Pfizer, Inc., New York) for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNETs) in patients with unresectable locally advanced or metastatic disease. In a

Присоединяйтесь к нашей
странице facebook

Herbal & Natural Medicine

Самая полная база данных о лекарственных травах, подтвержденная наукой

Работает на 55 языках
Травяные лекарства, подтвержденные наукой
Распознавание трав по изображению
Интерактивная карта GPS - отметьте травы на месте (скоро)
Прочтите научные публикации, связанные с вашим поиском
Ищите лекарственные травы по их действию
Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов

Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.